131 related articles for article (PubMed ID: 20401980)
1. Targeting opioid receptors: A new treatment for brain disorders.
Rahman S
CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):128. PubMed ID: 20401980
[No Abstract] [Full Text] [Related]
2. Antagonism of κ opioid receptor in the nucleus accumbens prevents the depressive-like behaviors following prolonged morphine abstinence.
Zan GY; Wang Q; Wang YJ; Liu Y; Hang A; Shu XH; Liu JG
Behav Brain Res; 2015 Sep; 291():334-341. PubMed ID: 26049060
[TBL] [Abstract][Full Text] [Related]
3. Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials.
Carlezon WA; Krystal AD
Depress Anxiety; 2016 Oct; 33(10):895-906. PubMed ID: 27699938
[TBL] [Abstract][Full Text] [Related]
4. LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders.
Rorick-Kehn LM; Witkin JM; Statnick MA; Eberle EL; McKinzie JH; Kahl SD; Forster BM; Wong CJ; Li X; Crile RS; Shaw DB; Sahr AE; Adams BL; Quimby SJ; Diaz N; Jimenez A; Pedregal C; Mitch CH; Knopp KL; Anderson WH; Cramer JW; McKinzie DL
Neuropharmacology; 2014 Feb; 77():131-44. PubMed ID: 24071566
[TBL] [Abstract][Full Text] [Related]
5. Antidepressant-like effects of kappa-opioid receptor antagonists in Wistar Kyoto rats.
Carr GV; Bangasser DA; Bethea T; Young M; Valentino RJ; Lucki I
Neuropsychopharmacology; 2010 Feb; 35(3):752-63. PubMed ID: 19924112
[TBL] [Abstract][Full Text] [Related]
6. Opioid system contribution to the antidepressant-like action of m-trifluoromethyl-diphenyl diselenide in mice: A compound devoid of tolerance and withdrawal syndrome.
Rosa SG; Pesarico AP; Tagliapietra CF; da Luz SC; Nogueira CW
J Psychopharmacol; 2017 Sep; 31(9):1250-1262. PubMed ID: 28857657
[TBL] [Abstract][Full Text] [Related]
7. Tritiated kappa receptor antagonist norbinal torphimine: synthesis and in vitro binding in three different tissues.
Márki A; Otvös F; Tóth G; Hosztafi S; Borsodi A
Life Sci; 2000; 66(1):43-9. PubMed ID: 10658923
[TBL] [Abstract][Full Text] [Related]
8. The marketing of 5-hydroxytryptamine: depression or anxiety?
Healy D
Br J Psychiatry; 1991 Jun; 158():737-42. PubMed ID: 1873625
[No Abstract] [Full Text] [Related]
9. Effects of U-50,488H, a kappa-opioid receptor agonist, on the learned helplessness model of depression in mice.
Ukai M; Suzuki M; Mamiya T
J Neural Transm (Vienna); 2002 Sep; 109(9):1221-5. PubMed ID: 12203050
[TBL] [Abstract][Full Text] [Related]
10. Kappa opioid receptor signaling in the brain: Circuitry and implications for treatment.
Crowley NA; Kash TL
Prog Neuropsychopharmacol Biol Psychiatry; 2015 Oct; 62():51-60. PubMed ID: 25592680
[TBL] [Abstract][Full Text] [Related]
11. The kappa-opioid antagonist GNTI reduces U50,488-, DAMGO-, and deprivation-induced feeding, but not butorphanol- and neuropeptide Y-induced feeding in rats.
Jewett DC; Grace MK; Jones RM; Billington CJ; Portoghese PS; Levine AS
Brain Res; 2001 Aug; 909(1-2):75-80. PubMed ID: 11478923
[TBL] [Abstract][Full Text] [Related]
12. The therapeutic potential of κ-opioids for treatment of pain and addiction.
Chavkin C
Neuropsychopharmacology; 2011 Jan; 36(1):369-70. PubMed ID: 21116263
[No Abstract] [Full Text] [Related]
13. Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors.
Jones RM; Hjorth SA; Schwartz TW; Portoghese PS
J Med Chem; 1998 Dec; 41(25):4911-4. PubMed ID: 9836606
[No Abstract] [Full Text] [Related]
14. [Central K1-opiate receptors and mechanisms of arrhythmogenesis].
Ugdyzhekova DS; Maslov LN; Lishmanov IB
Biull Eksp Biol Med; 1997 Jun; 123(6):656-8. PubMed ID: 9280519
[No Abstract] [Full Text] [Related]
15. The prefrontal cortex influence over subcortical and limbic regions governs antidepressant response by N=H/(M+R).
Salerian AJ; Altar CA
Psychiatry Res; 2012 Oct; 204(1):1-12. PubMed ID: 23022274
[TBL] [Abstract][Full Text] [Related]
16. The effect of kappa opioid receptor antagonism on energy expenditure in the obese Zucker rat.
Jarosz PA
Biol Res Nurs; 2007 Apr; 8(4):294-9. PubMed ID: 17456590
[TBL] [Abstract][Full Text] [Related]
17. A remarkable change of opioid receptor selectivity on the attachment of a peptidomimetic kappa address element to the delta antagonist, natrindole: 5'-[N2-alkylamidino)methyl]naltrindole derivatives as a novel class of kappa opioid receptor antagonists.
Olmsted SL; Takemori AE; Portoghese PS
J Med Chem; 1993 Jan; 36(1):179-80. PubMed ID: 8380614
[No Abstract] [Full Text] [Related]
18. Dynorphin, stress, and depression.
Knoll AT; Carlezon WA
Brain Res; 2010 Feb; 1314():56-73. PubMed ID: 19782055
[TBL] [Abstract][Full Text] [Related]
19. The role of the dynorphin/κ opioid receptor system in anxiety.
Hang A; Wang YJ; He L; Liu JG
Acta Pharmacol Sin; 2015 Jul; 36(7):783-90. PubMed ID: 25982631
[TBL] [Abstract][Full Text] [Related]
20. Dynorphin A(1-17)-induced feeding: pharmacological characterization using selective opioid antagonists and antisense probes in rats.
Silva RM; Grossman HC; Hadjimarkou MM; Rossi GC; Pasternak GW; Bodnar RJ
J Pharmacol Exp Ther; 2002 May; 301(2):513-8. PubMed ID: 11961051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
